The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards.
The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition.
“As we celebrate 50 years of the Prix Galien process, we are honored to announce this year’s Prix Galien USA nominees, which represent the determination and passion for change that serves as the driving force of life-changing innovation,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Committees, in a news release.
This year, the foundation nominated 26 pharmaceutical agents that have been FDA-approved for the market within the last five years, and show major potential to affect healthcare. The winners will be announced in October this year.
“While scientific discovery and medical innovation experts continue to fight against the current pandemic, this year’s nominees remind us how their work represents the next chapter of human progress in fighting disease,” said foundation chair Bruno Cohen. “As we quickly approach this year’s in-person and digital awards ceremony, the foundation continues to monitor the COVID-19 pandemic and will support guidelines from the Centers for Disease Control and Prevention and World Health Organization.”
The best pharmaceutical agents range from a prescription cannabidiol to treat seizures to medication to treat cardiomyopathy. Here are the 26 most innovative pharmaceutical agents of 2020, according to the Galien Foundation.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs